Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00554203 · ClinicalTrials.gov registry record · NA
Sulfasalazine and Endothelial Function
A NA study, sponsored by Boston University.
- Completed
- Registry status
- NA
- Development phase
- 60
- Enrollment target
NCT00554203 is a NA study that has completed, run by Boston University. The registered enrollment target is 60 participants.
The verdict
NCT00554203, a NA study, has completed, sponsored by Boston University.
- COMPLETED
- Registry status
- NA
- Development phase
- 60 participants
- Enrollment target
Study Summary
Experimental studies suggest that systemic inflammation leads to endothelial dysfunction and atherosclerosis. This study will examine the effects of the anti-inflammatory drug sulfasalazine on endothelial function in patients with coronary artery disease. Subjects will be treated with sulfasalazine or to placebo for six weeks. After a two-week rest period, subjects will cross over to the alternative treatment. Endothelium-dependent flow-mediated dilation of the brachial artery will be studied before and after each drug. We hypothesize that anti-inflammatory therapy will reverse endothelial dysfunction in patients with coronary artery disease.
Interventions
- DRUG Sulfasalazine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2003-07 |
| Est. Completion | 2007-12 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00554203
The ClinicalTrials.gov registry entry for NCT00554203 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boston University, which has 185 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Sulfasalazine is the first listed.
NCT00554203 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00554203 about?
NCT00554203 is a clinical study titled "Sulfasalazine and Endothelial Function". Experimental studies suggest that systemic inflammation leads to endothelial dysfunction and atherosclerosis. This study will examine the effects of the anti-inflammatory drug sulfasalazine on endothelial function in patients with coronary artery disease. Subjects will be treated with sulfasalazine ...
What is the current status of trial NCT00554203?
This trial is currently completed. It is a NA study. The enrollment target is 60 participants. The study started on 2003-07. Estimated completion is 2007-12.
What interventions are being tested in trial NCT00554203?
The interventions under investigation include: Sulfasalazine (DRUG).
Who is sponsoring clinical trial NCT00554203?
This trial is sponsored by Boston University, which has 185 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.